Dr. Dino Prato

For the last 15 years, Dr. Dino Prato and his team have been pioneering scientific breakthroughs that take an innovative, integrated, and highly effective approach to treatment. Dr. Prato and colleagues have recently published a peer-reviewed paper in the Open Journal of Medical Microbiology titled “Cancer and Infectious Causes.” Despite the fact that infections are responsible for about 20% of all cancers worldwide, most treatment approaches largely ignore these underlying causes, and they’re rarely addressed. Yet these infections can affect both the development of the cancer and its progression. Most cancer patients are never tested for these underlying infections and may never even know they have them. Latent infections can cause inflammation in the body, the mutation of genes, and can depress the immune system, all of which can create the “perfect storm” for the development and spread of cancers. Envita’s therapies take a revolutionary approach to treatment by targeting these underlying infections as part of cancer treatment protocols. “Most patients don’t know why they developed cancer in the first place. Envita tries to uncover these underlying causes in an effort to more effectively treat each patient’s disease,” says Dr. Dino Prato.
Dr. Dino Prato reasons: “These underlying infections play into the metastasis (spread) of the disease, and may play a vital role in the continual mutations we see within the same cancer patient. These infections ultimately can lead to debilitated immune compromised responses, which is why so many patients cannot fight cancer in the first place. We find when testing for detailed immune status with our patients, specifically CD56 and CD57, that natural killer cell viability and function are highly depressed with impaired activity and can be seen as an important prognostic indicator in cancer patients.”